What is Lyell Immunopharma Inc (LYEL) stock price today?

Lyell Immunopharma Inc (LYEL) currently trades at $19.73 per share. The stock has a market capitalization of $527.78M and a P/E ratio of —x.

Is LYEL stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Lyell Immunopharma Inc has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Lyell Immunopharma Inc's revenue and earnings?

Lyell Immunopharma Inc has trailing twelve-month (TTM) revenue of $36000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-16.06.

LYEL

Lyell Immunopharma Inc

NASDAQ: LYEL · HEALTHCARE · BIOTECHNOLOGY

$19.73

-4.22% today

Updated 2026-04-30

Market cap

$527.78M

P/E ratio

—

P/S ratio

14,660.60x

EPS (TTM)

$-16.06

Dividend yield

—

52W range

$8 – $45

Volume

0.1M

Market cap

$527.78M

P/E ratio

—

P/S ratio

14,660.60x

EPS (TTM)

$-16.06

Dividend yield

—

52W range

$8 – $45

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$34.80

+76.38%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy2 Buy0 Hold0 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-32.62M

- Revenue declining -45.50% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$84.68M	$130000.00	$61000.00	$36000.00	$36000.00
Net income	$-183.12M	$-234.63M	$-342.99M	$-274.45M	$-140.72M
EPS	—	—	—	—	$-16.06
Free cash flow	$-193.83M	$-166.38M	$-162.86M	$-150.80M	$-32.62M
Profit margin	-216.24%	-180,486.15%	-562,285.25%	-762,355.56%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-09	SHAH, SMITAL	Buy	140,000	—
2026-03-06	ARCH, VENTURE PARTNERS IX, LLC	Buy	488,090	$25.61
2026-03-06	ARCH, VENTURE FUND XIII, L.P.	Buy	488,090	$25.61

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LYEL	$527.78M	24	2.7	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Lyell Immunopharma Inc trades at $19.73. Our Smart Value Score of 24/100 indicates the stock is weak. TTM revenue stands at $36000.00.

Frequently asked questions

What is Lyell Immunopharma Inc's stock price?

Lyell Immunopharma Inc (LYEL) trades at $19.73.

Is Lyell Immunopharma Inc overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of Lyell Immunopharma Inc (LYEL)?

The analyst target price is $34.80, representing +76.4% upside from the current price of $19.73.

What is Lyell Immunopharma Inc's revenue?

TTM revenue is $36000.00.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio14,660.60x

ROE-87.00%

Beta-0.07

50D MA$22.59

200D MA$19.69

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.1M

Performance

1 week-5.38%

1 month+15.00%

3 months-10.52%

YTD-26.51%

1 year—

3 years—

5 years—

Compare

LYEL vs LLY →LYEL vs JNJ →LYEL vs ABBV →Stock screener →